No phaseCompleted
Strategy TO Prevent Decompensated Heart Failure (#STOP-DHF)
A Multi-centre, Prospective, Single-arm, Open-label Trial With a Prespecified Effectiveness Endpoint to Evaluate the Benefits of Haemodynamically Guided Treatment Using the Seerlinq HeartCore System in Heart-failure Patients.
- Sponsor
- Seerlinq s. r. o. (Academic or other)
- Enrolment
- 330 enrolled
- Conditions
- Heart Failure; Remote Monitoring
- Interventions
- Seerlinq Telemedical Monitoring System
- Ages
- adults, older adults
- Registry
- NCT06641921
Full record on ClinicalTrials.gov
From the registry
The goal of this prospective, multicenter, single-arm, open-label clinical trial (Strategy TO Prevent Decompensated Heart Failure) is to evaluate the 12-month incidence of heart failure hospitalization (HFH) and all cause mortality in patients managed with haemodynamically guided treatment using the Seerlinq telemedical monitoring system.
Primary outcomes
- Heart failure hospitalization and mortality
History
Last registry update
Study completion
Primary completion
Registered
Started